casein kinase 2, alpha 1 polypeptide subunit | Casein kinase 2 (CK2) family | IUPHAR/BPS Guide to PHARMACOLOGY

Top ▲

casein kinase 2, alpha 1 polypeptide subunit

target has curated data in GtoImmuPdb

Target id: 1549

Nomenclature: casein kinase 2, alpha 1 polypeptide subunit

Abbreviated Name: CK2-A1

Family: Casein kinase 2 (CK2) family

Annotation status:  image of an orange circle Annotated and awaiting review. Please contact us if you can help with reviewing.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 391 20p13 CSNK2A1 casein kinase 2 alpha 1
Mouse - 391 2 Csnk2a1 casein kinase 2, alpha 1 polypeptide
Rat - 391 3q41 Csnk2a1 casein kinase 2 alpha 1
Previous and Unofficial Names
casein kinase II subunit alpha | CK II alpha | casein kinase 2
Database Links
BRENDA
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of CK2alpha.
PDB Id:  3AT2
Resolution:  1.6Å
Species:  Human
References:  9
Image of receptor 3D structure from RCSB PDB
Description:  Human CK2 catalytic domain in complex with AMPPN.
PDB Id:  3NSZ
Resolution:  1.3Å
Species:  Human
References:  6
Image of receptor 3D structure from RCSB PDB
Description:  Structural basis of CX-4945 binding to human protein kinase CK2.
PDB Id:  3NGA
Ligand:  silmitasertib
Resolution:  2.71Å
Species:  Human
References:  6
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of human protein kinase CK2 in complex with the inhibitor CX-5011.
PDB Id:  3PE2
Ligand:  CX-5011
Resolution:  1.9Å
Species:  Human
References:  2
Enzyme Reaction
EC Number: 2.7.11.1

Download all structure-activity data for this target as a CSV file

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
compound 2c [PMID: 22115617] Hs Inhibition 7.1 pKi 8
pKi 7.1 (Ki 8.3x10-8 M) [8]
silmitasertib Hs Inhibition 9.0 pIC50 10
pIC50 9.0 (IC50 1x10-9 M) [10]
compound 1a [PMID: 24900749] Hs Inhibition 8.0 pIC50 5
pIC50 8.0 (IC50 1x10-8 M) [5]
Inhibitor Comments
The CK2 inhibitor TBB (PubChem CID 1694) has an IC50 of 500nM vs. the human CK2α catalytic subunit CSNK2A1 [3].
DiscoveRx KINOMEscan® screen
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan
Reference: 4,11

Key to terms and symbols Click column headers to sort
Target used in screen: CSNK2A1
Ligand Sp. Type Action Value Parameter
tamatinib Hs Inhibitor Inhibition 7.2 pKd
sunitinib Hs Inhibitor Inhibition 6.1 pKd
fedratinib Hs Inhibitor Inhibition 6.0 pKd
staurosporine Hs Inhibitor Inhibition 6.0 pKd
KW-2449 Hs Inhibitor Inhibition 5.9 pKd
PP-242 Hs Inhibitor Inhibition 5.9 pKd
SU-14813 Hs Inhibitor Inhibition 5.7 pKd
dovitinib Hs Inhibitor Inhibition 5.6 pKd
lestaurtinib Hs Inhibitor Inhibition 5.6 pKd
TG-100-115 Hs Inhibitor Inhibition 5.6 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.

http://www.millipore.com/techpublications/tech1/pf3036
http://www.reactionbiology.com/webapps/main/pages/kinase.aspx


Reference: 1,7

Key to terms and symbols Click column headers to sort
Target used in screen: CK2/CK2a
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
PI 3-Kg inhibitor Hs Inhibitor Inhibition 3.1 -13.0 -12.0
casein kinase II inhibitor III Hs Inhibitor Inhibition 13.1 12.0 -8.0
SB 218078 Hs Inhibitor Inhibition 16.7 74.0 101.0
JNK inhibitor V Hs Inhibitor Inhibition 22.1 58.0 15.0
PI 3-Kg inhibitor II Hs Inhibitor Inhibition 22.6 32.0 2.0
PKR inhibitor, negative control Hs Inhibitor Inhibition 26.5 41.0 4.0
GSK-3 inhibitor XIII Hs Inhibitor Inhibition 27.0 43.0 -2.0
STO609 Hs Inhibitor Inhibition 28.3 22.0 -4.0
PKR inhibitor Hs Inhibitor Inhibition 48.2 30.0 1.0
isogranulatimide Hs Inhibitor Inhibition 52.6 60.0 21.0
Displaying the top 10 most potent ligands  View all ligands in screen »
Immunopharmacology Comments
CSNK2A1 is included in Guide to IMMUNOPHARMACOLOGY as it is a subunit of the casein kinase 2 complex.

References

Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1039-45. [PMID:22037377]

2. Battistutta R, Cozza G, Pierre F, Papinutto E, Lolli G, Sarno S, O'Brien SE, Siddiqui-Jain A, Haddach M, Anderes K et al.. (2011) Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. Biochemistry, 50 (39): 8478-88. [PMID:21870818]

3. Battistutta R, Mazzorana M, Sarno S, Kazimierczuk Z, Zanotti G, Pinna LA. (2005) Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole. Chem. Biol., 12 (11): 1211-9. [PMID:16298300]

4. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1046-51. [PMID:22037378]

5. Dowling JE, Alimzhanov M, Bao L, Block MH, Chuaqui C, Cooke EL, Denz CR, Hird A, Huang S, Larsen NA et al.. (2013) Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett, 4 (8): 800-5. [PMID:24900749]

6. Ferguson AD, Sheth PR, Basso AD, Paliwal S, Gray K, Fischmann TO, Le HV. (2011) Structural basis of CX-4945 binding to human protein kinase CK2. FEBS Lett., 585 (1): 104-10. [PMID:21093442]

7. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J., 451 (2): 313-28. [PMID:23398362]

8. Janeczko M, Orzeszko A, Kazimierczuk Z, Szyszka R, Baier A. (2012) CK2α and CK2α' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur J Med Chem, 47 (1): 345-50. [PMID:22115617]

9. Kinoshita T, Sekiguchi Y, Fukada H, Nakaniwa T, Tada T, Nakamura S, Kitaura K, Ohno H, Suzuki Y, Hirasawa A et al.. (2011) A detailed thermodynamic profile of cyclopentyl and isopropyl derivatives binding to CK2 kinase. Mol. Cell. Biochem., 356 (1-2): 97-105. [PMID:21735094]

10. Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E et al.. (2011) Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J. Med. Chem., 54 (2): 635-54. [PMID:21174434]

11. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol., 17 (11): 1241-9. [PMID:21095574]

How to cite this page

Casein kinase 2 (CK2) family: casein kinase 2, alpha 1 polypeptide subunit. Last modified on 23/08/2017. Accessed on 08/12/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1549.